[1] Gill JS, Hunter GJ, Gane G, et al.  Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy[J]. Am Heart J, 1993, 126(2): 390-398.   doi: 10.1016/0002-8703(93)91056-K
[2] Estorch M, Serra-Grima R, Flotats A, et al.  Myocardial sympathetic innervation in the athlete's sinus bradycardia: is there selective inferior myocardial wall denervation?[J]. J Nucl Cardiol, 2000, 7(4): 354-358.   doi: 10.1067/mnc.2000.105550
[3] Ogita H, Shimonagata T, Fukunami M, et al.  Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study[J]. Heart, 2001, 86(6): 656-660.   doi: 10.1136/heart.86.6.656
[4] Merlet P, Valette H, Dubois-Rande JL, et al.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure[J]. J Nucl Med, 1992, 33(4): 471-477.
[5] Merlet P, Pouillart F, Dubois-Rande'JL, et al.  Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart[J]. J Nucl Med, 1999, 40(2): 224-231.
[6] Takeishi Y, Atsumi H, Fujiwara S, et al.  ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure[J]. J Nucl Med, 1997, 38(7): 1085-1089.
[7] Matsui T, Tsutamoto T, Maeda K, et al.  Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors[J]. Circ J, 2002, 66(6): 537-543.   doi: 10.1253/circj.66.537
[8] Merlet P, Benvenuti C, Moyse D, et al.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy[J]. J Nucl Med, 1999, 40(6): 917-923.
[9] Zipes DP, Camm AJ, Borggrefe M, et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)[J]. J Am Coll Cardiol, 2006, 48(5): e247-e346.   doi: 10.1016/j.jacc.2006.07.010
[10] Bardy GH, Lee KL, Mark DB, et al.  Amiodarone or an implantable defibrillator for congestive heart failure[J]. N Engl J Med, 2005, 352(3): 225-237.   doi: 10.1056/NEJMoa043399
[11] Arora R, Ferrick KJ, Nakata T, et al.  I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator[J]. J Nucl Cardiol, 2003, 10(2): 121-131.   doi: 10.1067/mnc.2003.2
[12] Nagahara D, Nakata T, Hashimoto A, et al.  Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function[J]. J Nucl Med, 2008, 49(2): 225-233.   doi: 10.2967/jnumed.107.042564
[13] Kioka H, Yamada T, Mine T, et al.  Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging[J]. Heart, 2007, 93(10): 1213-1218.   doi: 10.1136/hrt.2006.094524
[14] Zipes DP.  Influence of myocardial ischemia and infarction on autonomic innervation of heart[J]. Circulation, 1990, 82(4): 1095-1105.   doi: 10.1161/01.CIR.82.4.1095
[15] Dae MW, Herre JM, O'Connell JW, et al.  Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction[J]. J Am Coll Cardiol, 1991, 17(6): 1416-1423.   doi: 10.1016/S0735-1097(10)80156-1
[16] Simôes MV, Barthel P, Matsunari I, et al.  Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction[J]. Eur Heart J, 2004, 25(7): 551-557.   doi: 10.1016/j.ehj.2004.02.016
[17] Sasano T, Abraham R, Chang KC, et al.  Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction[J]. J Am Coll Cardiol, 2008, 51(23): 2266-2275.   doi: 10.1016/j.jacc.2008.02.062
[18] Tomoda H, Yoshioka K, Shiina Y, et al.  Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina[J]. Am Heart J, 1994, 128(3): 452-458.   doi: 10.1016/0002-8703(94)90616-5
[19] Simula S, Vanninen E, Viitanen L, et al.  Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary disease[J]. J Nucl Med, 2002, 43(1): 1-7.
[20] Hattori N, Tamaki N, Hayashi T, et al.  Regional abnormality of iodine-123-MIBG in diabetic hearts[J]. J Nucl Med, 1996, 37(12): 1985-1990.
[21] Nagamachi S, Fujita S, Nishii R, et al.  Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus[J]. J Nucl Cardiol, 2006, 13(1): 34-42.   doi: 10.1016/j.nuclcard.2005.11.009
[22] Gill JS, Hunter GJ, Gane J, et al.  Asymmetry of cardiac[123I]metaiodobenzylguanidine scans in patients with ventricular tachy-cardia and a"clinically normal"heart[J]. Br Heart J, 1993, 69(1): 6-13.   doi: 10.1136/hrt.69.1.6
[23] Wakasugi S, Fischman AJ, Babich JW, et al.  Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy[J]. J Nucl Med, 1993, 34(8): 1283-1286.
[24] Carrió I, Estorch M, Berná L, et al.  Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity[J]. J Nucl Med, 1995, 36(11): 2044-2049.